ARID1A and the gene 'switches' that shape pulmonary arterial hypertension
The Chromatin Remodeling Factor ARID1a and the Epigenetic Landscape In Pulmonary Arterial Hypertension
This project looks at whether changes in the ARID1A gene and related epigenetic switches drive the blood-vessel scarring that causes pulmonary arterial hypertension.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11289363 on NIH RePORTER |
What this research studies
From a patient's perspective, researchers will examine how the ARID1A protein and other epigenetic regulators change the way genes are turned on or off in lungs affected by PAH. They will use lab models, including cells and animal models, and modern genomic tools (like ATAC-seq) to map chromatin accessibility and gene activity in diseased pulmonary vessels. The team will probe how ARID1A interacts with the enzyme EZH2 and how imbalances may promote vascular remodeling and cell survival. Results aim to point to molecular pathways that could be targeted to slow or reverse vessel scarring.
Who could benefit from this research
Good fit: People diagnosed with pulmonary arterial hypertension who are willing to provide clinical information or tissue/blood samples, and who can travel to or work with the study site, would be ideal candidates for any human sampling activities.
Not a fit: People without PAH, those with other forms of pulmonary hypertension, or patients seeking immediate therapeutic benefit should not expect direct personal benefit from this laboratory-focused project.
Why it matters
Potential benefit: If successful, this work could identify new molecular targets to develop treatments that prevent or reverse the blood-vessel remodeling that causes PAH.
How similar studies have performed: ARID1A-related research has revealed important roles in cancer and cell regulation, but applying ARID1A and chromatin-mapping approaches specifically to PAH is largely novel.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Hadri, Lahouaria — Icahn School of Medicine at Mount Sinai
- Study coordinator: Hadri, Lahouaria
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.